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Abstract
Severe trauma-related bleeding is associated with high mortality. Standard coagulation tests provide limited
information on the underlying coagulation disorder. Whole-blood viscoelastic tests such as rotational
thromboelastometry or thrombelastography offer a more comprehensive insight into the coagulation process in
trauma. The results are available within minutes and they provide information about the initiation of coagulation,
the speed of clot formation, and the quality and stability of the clot. Viscoelastic tests have the potential to guide
coagulation therapy according to the actual needs of each patient, reducing the risks of over- or under-transfusion.
The concept of early, individualized and goal-directed therapy is explored in this review and the AUVA Trauma
Hospital algorithm for managing trauma-induced coagulopathy is presented.
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Introduction
Major brain injury and uncontrolled blood loss remain
the primary causes of early trauma-related mortality
[1-3]. One-quarter to one-third of trauma patients exhi-
bit trauma-induced coagulopathy (TIC) [4,5], which is
associated with increased rates of massive transfusion
(MT) and multiple organ failure (MOF), prolonged
intensive care unit and hospital stays, and a four-fold
increase in mortality [4]. Most patients with coagulopa-
thy also have uncontrolled bleeding, and early diagnosis
of the underlying coagulation disorder is paramount for
effective treatment.
One major challenge in treating severely bleeding
trauma patients is to determine whether the blood loss
is attributable to surgical causes or coagulopathy. If the
patient is coagulopathic, it is paramount to characterize
the cause of the coagulopathy and whether thrombin
generation is impaired or clot quality or stability is
diminished. Recent data suggest that whole-blood vis-
coelastic tests, such as thromboelastometry (ROTEM®,
Tem International GmbH, Munich, Germany) or throm-
belastography (TEG®, Haemonetics Corp., Braintree,
MA, USA) portray trauma induced coagulopathy (TIC)
more accurately and substantially faster than standard
coagulation tests [6-8]. There is increasing evidence that
these coagulation monitoring devices are helpful in
guiding coagulation therapy for heavily bleeding trauma
patients according to their actual needs [9].
The intention of this review is to examine the concept
of individualized, early, goal-directed therapy for TIC,
using viscoelastic tests and targeted coagulation therapy.
In addition, the AUVA Trauma Hospital algorithm for
managing TIC is presented.
Value of standard coagulation tests
Fast, reliable diagnosis and characterization of TIC is
important. Standard coagulation tests (e.g. prothrombin
time [PT], international normalized ratio [INR], pro-
thrombin time index [PTI] and activated partial throm-
boplastin time [aPTT]) fail to accurately describe the
complex nature of TIC for several reasons [4,5]. In vivo
coagulation occurs primarily on the surface of platelets
and tissue factor-bearing cells [10], and red blood cells
(RBCs) also play a significant role in haemostasis [11].
Standard coagulation tests are performed using plasma
in the absence of blood cells (these are removed by cen-
trifugation). Also, these tests are stopped upon forma-
tion of the first fibrin strands, when only ~5% of the
total thrombin has been generated [12]. Moreover, these
tests do not assess the quality/the strength of the clot.
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Hyperfibrinolysis is recognized as a potential contributor
to mortality in trauma [13-15], and this aspect is not
assessed by standard coagulation tests [16].
Coagulation factors do not decrease homogeneously in
severe bleeding. Although there may be a tendency
towards excessive thrombin generation, coagulation fac-
tor levels are decreased and fibrinogen appears to reach
critical levels at an early stage [17-19]. Therefore, mea-
surement of fibrinogen concentration is strongly recom-
mended in trauma patients [14,19]. However, when
using artificial colloids, falsely high fibrinogen levels are
recorded by some coagulation analysers that employ the
Clauss method [20,21]. Artificial colloids also impair
fibrin polymerization, and standard laboratory measure-
ment does not represent fibrinogen functionality [22].
Another shortcoming of standard coagulation tests,
including fibrinogen concentration measurement, is that
the results are available only after a substantial time
delay. Median turnaround times of 78-88 minutes have
been reported [23,24].
In summary, standard coagulation tests are unable to
characterize the complex nature of TIC. They are time-
consuming and offer little prognostic value regarding
transfusion requirements [25].
Role of thromboelastometry/thrombelastography
Trauma care providers are increasingly aware that vis-
coelastic coagulation monitors such as thromboelasto-
metry (ROTEM) and thrombelastography (TEG) are
valuable alternatives to standard coagulation testing,
providing a more comprehensive overview of the coagu-
lation process [6,8,23,26-29]. In contrast to most stan-
dard coagulation measurements, ROTEM and TEG can
be used as point-of-care methods. Viscoelastic tests are
performed in whole blood as opposed to plasma, which
provides a better reflection of the in vivo situation,
avoids the need for centrifugation and allows initial
results to be available within minutes [23,30].
ROTEM and TEG tests provide dynamic information
on the speed of coagulation initiation, kinetics of clot
growth, clot strength, and breakdown of the clot [16,31].
The ROTEM device uses a plastic pin immersed verti-
cally into a cup containing the blood sample; the pin is
rotated slowly, backwards and forwards, through an
angle of 4.75°. The device has four channels, allowing
four tests to be performed simultaneously. Two basic
ROTEM tests that use intrinsic activation (INTEM) and
extrinsic activation (EXTEM) provide information on
the general coagulation status (impaired, normal, and
hypercoagulable). Figure 1 shows examples of EXTEM
plots with normal and impaired coagulation. A set of
standard reagents can additionally be used to character-
ize coagulopathy. For example, the FIBTEM test, which
comprises the EXTEM assay with added cytochalasin D
to inhibit platelets, provides information on the fibrin
component of the clot.
The TEG device uses a stationary torsion wire and the
cup is rotated. TEG is a two channel system that uses
either kaolin as an activator or a combination of kaolin
and tissue factor (’rapid TEG’ or ‘r-TEG’ assay). The
Figure 1 Examples of ROTEM traces using the EXTEM test: a. normal test result. b. reduced maximum clot firmness (MCF). c. delayed
initiation of coagulation (prolonged coagulation time [CT]). d. prolonged CT and reduced MCF. e. hyperfibrinolysis.
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functional fibrinogen test is equivalent to the ROTEM
FIBTEM test. These methods and devices are described
in detail elsewhere [16,31].
Assessment of platelet function
Platelet count provides quantitative information on plate-
let numbers, but it provides no information on platelet
function. Prior treatment with platelet inhibitors such as
aspirin or thienopyridines is commonly encountered
among emergency room patients and, although platelet
function may potentially influence patient outcomes [32],
platelet inhibitor therapy cannot be assessed adequately
by standard viscoelastic analyses [33]. POC monitoring
devices allowing rapid assessment of platelet function (e.
g. Multiplate®; Roche Diagnostics, Munich, Germany)
have been developed recently [34]. Whole blood is added
to test cells which incorporate two independent sensor
units. Platelet aggregation takes place on the sensor units
following addition of a platelet activator. Different plate-
let activators are used such as adenosine diphosphate
(ADPtest), arachidonic acid (ASPItest), and thrombin
receptor-activating peptide-6 (TRAP-6; TRAPtest). The
platelets’ ability to adhere to the metal sensors and build
aggregates is measured by the electrical resistance change
between two sensor wires. The impedance change
between each pair of wires is recorded as an aggregation
curve and expressed in “aggregation units” (U). In the
AUVA trauma hospital, Mulitplate was used as a diag-
nostic tool for assessing platelet function in all patients
admitted to the ER between 2009 and 2011 [32]. In light
of our data published in 2011, [32] we now use Multi-
plate only in patients who are unconscious (meaning that
anamnesis is impossible) or known to be taking platelet
inhibitor medication.
Rationale for massive transfusion protocols
It has been shown that the majority of massively trans-
fused patients who exsanguinated within the first 24
hours after hospital admission received insufficient
amounts of fresh frozen plasma (FFP) and platelet con-
centrate (PC) [35]. Inadequate replacement of coagula-
tion factors during the initial care was identified as the
main cause of prolonged INR upon admission to the
intensive care unit (ICU) [36]. Recent data indicate that
early and aggressive transfusion of FFP and PC is asso-
ciated with improved survival rates among major trauma
patients [37-42]. To increase the effectiveness of coagu-
lation therapy, massive transfusion protocols (MTPs)
have been implemented. Predefined sets of RBC concen-
trate, FFP and PC are issued by the blood bank after the
activation of such MTPs [43,44]. However, MTPs vary
in format between trauma centres, with different ratios
of FFP to RBCs and PC [45]. MT prediction scores have
been developed for early identification of at-risk
patients, with the aim of initiating MTPs as early as pos-
sible thereby minimizing treatment delays. These scores
are based on anatomic findings and/or rapidly available
laboratory data such as PT and base deficit [46-49].
What is the optimal ratio of FFP:RBC?
It has long been assumed that high-volume plasma
replacement therapy may potentially avoid or correct
coagulopathy in severely bleeding patients. A computer
model by Hirshberg et al. has indicated that late transfu-
sion of plasma may be insufficient for preventing or cor-
recting coagulopathy [50]. Moreover, the optimum FFP:
RBC replacement ratio was calculated in the same study
to be approximately 2:3 [50]. Similarly, data from a mili-
tary centre show that the optimal FFP:RBC ratio for
minimizing mortality among trauma patients receiving
MT is close to 1:1.4 [37]. A retrospective analysis of
civilian trauma patients reported that a high FFP:RBC
ratio (> 1:1) significantly lowers intraoperative, 24-hour
and 30-day mortality [42]. An abundance of studies sup-
port early and aggressive coagulation management with
FFP [51]. However, the optimal ratio of FFP:RBC is still
under discussion [7,52,53].
For example, Kashuk et al. suggest that the optimal
ratio of FFP:RBC appears to be in the range of 1:2 to 1:3
[7], with no improvement in survival rate among
patients receiving higher ratios. More recently, Daven-
port et al. found no improvement in coagulation status
when FFP:RBC were transfused in a ratio of 1:1 com-
pared with 1:2 or 3:4 [52]. Simmons et al. reported data
from the Iraq War in which a change of clinical practice
guidelines toward higher FFP:RBC ratios resulted in sig-
nificantly higher FFP transfusion but no improvement in
survival [54]. Similarly, implementation of an MTP tar-
geting an FFP:RBC ratio of 1:1 in a Scandinavian trauma
centre significantly increased transfusion of FFP without
improving mortality [55].
Timing of haemostatic intervention is crucial
There is no doubt that coagulation therapy should be
started as early as possible. Riskin et al. reported a signifi-
cant reduction in mortality from 45% to 19% after imple-
mentation of an MTP despite unchanged FFP:RBC ratios.
The most likely reason for the improvement was a signif-
icant reduction in mean time to administration of FFP,
from 254 to 169 minutes [56]. Early haemostatic therapy
appears to prevent the development of coagulopathy in
some patients, eliminating the need for MT; plasma
transfusion seems to be most effective during the first 2-
3 hours of care for massively bleeding patients [57].
FFP: safety and the need for selective use
High-volume FFP transfusion is associated with consid-
erable side effects [55,58-61]. Chaiwat et al. reported a
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dose-dependent relationship between FFP transfusion
and acute respiratory distress syndrome (ARDS) in
trauma patients [58]. In another study, FFP transfusion
was independently associated with increased risk of
MOF and ARDS in patients who survived beyond 48
hours [62].
There is little evidence that patients receiving < 10
units (U) of RBCs benefit from FFP transfusion. Inaba et
al. showed that in non-MT trauma patients (< 10 U
RBC/24 hours), plasma administration increased compli-
cations (e.g. ARDS, pneumonia, sepsis and MOF), with-
out improving survival [59]. Other data show a greater
increase in side effects with FFP among patients receiv-
ing < 6 U RBCs within the first 6 hours [60]. Recently,
Sambasivan et al. analysed outcome data form 1,788
non-MT patients (< 10 U RBC/24 hours) who received
FFP and PC. A high ratio of FFP:RBC and PC:RBC was
associated with fewer ventilator-free and fewer ICU-free
days [61]. Therefore, early identification of patients who
are prone to MT seems important.
In summary, FFP transfusion is associated with serious
side effects, and transfusion triggers should be chosen
carefully. In particular, patients receiving < 10 U RBCs
do not appear to benefit from FFP transfusion.
Concept of early and individualized goal-directed
coagulation therapy
In contrast to a fixed ratio of FFP:PC:RBC, goal-directed
coagulation therapy aims to adapt treatment to the
actual needs of the individual patient, based on viscoe-
lastic test results (Figure 2) [6,8]. The short turnaround
times of ROTEM and TEG assays allow rapid diagnostic
testing and individualized drug therapy to be based on
test results, with a feedback loop to monitor and opti-
mize treatment effectiveness and to minimize side-
effects. This “theragnostic” concept offers several poten-
tial advantages, and these are discussed below.
Rapid assessment of coagulation status and prediction of
the need for massive transfusion
In severe trauma patients, it is crucial to receive rapid
information on the patient’s current coagulation status.
The first ROTEM or TEG test results are available
within minutes [30]. Low maximum clot firmness
(MCF) in EXTEM, INTEM and FIBTEM or maximum
amplitude (MA, the equivalent TEG parameter) has
been identified as an important determinant of RBC
transfusion [23,30,63-67]. In one study, MA but not
standard coagulation tests (INR, PT, aPTT) was predic-
tive for blood product transfusions [66]. Leemann et al.
showed that low INTEM MCF and low haemoglobin
levels were independent risk factors for MT [63]. TEG
clot strength (G) on admission to the ER has been
reported to provide consistent prediction of MT in
trauma patients [65]. Davenport et al. observed that
ROTEM clotting times in trauma patients show only a
trend toward prolongation in coagulopathic patients
(116 vs. 66 seconds; p = 0.0068). However, EXTEM clot
amplitude < 35 mm at 5 minutes was identified as a
predictor of MT with a detection rate of 71% [23]. A
retrospective study of major trauma patients (ISS > 16)
showed that a low FIBTEM amplitude (< 4 mm) and/or
a low EXTEM amplitude (< 35 mm) at 10 minutes
(CA10) reliably predicts MT [30].
AUVA TRAUMA HOSPITAL TREATMENT
ALGORITHM FOR TIC - DIAGNOSIS
To provide rapid information on the coagulation sta-
tus of major trauma patients: run ROTEM tests
(EXTEM, INTEM, FIBTEM and APTEM) to assess
clotting times and/or clot quality on admission to
the ER. For patients who are unconscious or known
to be taking platelet inhibitor medication, Multi-
plate tests (adenosine diphosphate [ADP] test, ara-
chidonic acid [ASPI] test, and thrombin receptor
activating peptide-6 [TRAP] test) are also performed,
to assess platelet function.
Improving and maintaining clot quality in TIC
Based on the evidence available, it appears reasonable to
focus goal-directed coagulation therapy on the mainte-
nance or restoration of clot strength. Clot strength is
determined by interactions between the fibrin network,
activated platelets and activated factor XIII.
Fibrinogen supplementation
Fibrinogen seems to reach critically low levels very early
after trauma [9,13,23,30]. Current European guidelines
recommend a plasma fibrinogen concentration in
trauma patients of no less than 1.5-2.0 g/L [29]. How-
ever, there is limited evidence that fibrinogen adminis-
tration improves outcomes in trauma patients. A
retrospective military study reported increased survival
among patients receiving a high fibrinogen:RBC ratio
(0.48 g fibrinogen per unit of RBCs), compared with
those receiving a lower ratio (0.1 g fibrinogen per unit
of RBC) [68].
FFP is one potential source of fibrinogen, but it is col-
lected from healthy volunteers who may occasionally
have low fibrinogen levels. Fibrinogen concentrations of
~2 g/L have been found in both FFP and solvent-deter-
gent (SD) plasma [69]. Chowdhury et al. compared
changes in coagulation factor levels after FFP transfu-
sion of 12 mL/kg bodyweight or 35 mL/kg bodyweight,
and observed a substantial increase in fibrinogen solely
in the high-FFP volume group [70]. Prior to infusion,
FFP must be thawed and this is a time-consuming pro-
cess. Pre-thawing of FFP may avoid this delay, but sto-
rage time is limited. Lyophilized plasma, which is
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Figure 2 ROTEM-guided treatment algorithm: managing trauma-induced coagulopathy and diffuse microvascular bleeding (AUVA
Trauma Hospital, Salzburg, Austria). The algorithm represents standard operating procedure for ROTEM-guided haemostatic therapy upon
admission of trauma patients to the emergency room. In parentheses: haemostatic agents suggested for use in clinics where coagulation factor
concentrates are not available. * For patients who are unconscious or known to be taking platelet inhibitor medication, Multiplate tests
(adenosine diphosphate [ADP] test, arachidonic acid [ASPI] test, and thrombin receptor activating peptide-6 [TRAP] test) are also performed. § If
decreased ATIII is suspected or known, consider co-administration of ATIII. † Any major improvement in APTEM parameters compared to
corresponding EXTEM parameters may be interpreted as a sign of hyperfibrinolysis. ‡ Only for patients not receiving TXA at an earlier stage of
the algorithm. Traumatic brain injury: platelet count 80,000-100,000/μl. Normal values: EXTEM/APTEM coagulation time (CT): 38-79 seconds;
EXTEM/APTEM clot amplitude at 10 minutes (CA10): 43-65 mm; EXTEM/APTEM maximum lysis (ML) < 15%; FIBTEM CA10: 7-23 mm; INTEM CT:
100-240 seconds. CA10, clot amplitude at 10 minutes; BGA, blood gas analysis; BW, body weight; Ca, calcium; CT, clotting time; FFP, fresh frozen
plasma; ISS, injury severity score; MCF, maximum clot firmness; ML, maximum lysis; PCC, prothrombin complex concentrate; TXA, tranexamic acid.
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immediately available in the ER, represents a possible
future solution to these problems [71].
Cryoprecipitate, another source of fibrinogen, is still
available in the US and the UK, but it has been with-
drawn from some European countries in response to
significant safety concerns [72]. The fibrinogen content
of a unit of cryoprecipitate can vary widely, from 120 to
796 mg [73]. In patients not receiving plasma compo-
nents within the preceding 2 hours, cryoprecipitate has
been reported to produce a mean increase in fibrinogen
concentration of ~0.06 g/U [74]. If using cryoprecipitate
to increase plasma fibrinogen concentration, European
Guidelines recommend transfusion of 15-20 U in a 70-
kg adult [29]. Only limited data show improved survival
following transfusion of cryoprecipitate in trauma
patients [62].
Fibrinogen concentrate is licensed in some European
countries for congenital and acquired bleeding. It can be
reconstituted easily and quickly using sterile water or
saline [75], allowing rapid and controlled dosing.
Approximately 3 g of fibrinogen concentrate is required
to raise the plasma concentration by 1 g/L in a 70-kg
patient [76]. Fibrinogen concentrate can be administered
without thawing or cross-matching, significantly redu-
cing time to infusion [8]. In emergency cases, adminis-
tration of 6 g in 1-2 minutes has been reported [76].
Post-treatment improvements in clot formation and clot
strength can be monitored using viscoelastic tests [8,76].
The safety profile of fibrinogen concentrate appears to
be favourable with a low risk of thromboembolic events
[77-79], although the available data cannot be consid-
ered as definitive in this regard.
AUVA TRAUMA HOSPITAL TREATMENT
ALGORITHM FOR TIC
FIBTEM CA10 < 7 mm suggests insufficient fibrin
clot formation. Fibrinogen concentrate should be
administered until a FIBTEM CA10 of 10-12 mm is
reached.
Platelet transfusion
Platelets are important determinants of clot quality and
serve as a matrix for coagulation factors [11]. Upon ER
admission, platelet count < 150,000/μL has been
reported in only 4% of trauma patients with an injury
severity score (ISS) of 5 and in 18% of patients with ISS
> 45 [80].
In bleeding trauma patients, it is recommended to
maintain platelet count > 50,000/μL and in patients with
substantial brain injury, a platelet count > 100,000/μL is
suggested as optimal [29]. However, the value of platelet
transfusion in a fixed, predefined ratio for the manage-
ment of TIC is currently unclear. The reported
improvements in survival associated with platelet trans-
fusion are subject to survival and selection biases similar
to those seen with FFP and the efficacy and safety of
platelet transfusion in a predetermined ratio has not
been established. Holcomb et al. reported improved
early and late survival and decreased rates of haemor-
rhagic deaths in patients receiving a high ratio of PC:
RBC. As a potential side effect of increased platelet
transfusion, MOF increased as the PC:RBC ratio
increased [81]. The MTP published by Dirks et al.
resulted in a significant increase in PC transfusion with-
out any improvement in the survival rate [55]. Similar
results were reported by Simmons et al., who observed
that the introduction of new clinical practice guidelines
forcing early platelet transfusion resulted in no survival
benefit [54]. Thus, platelet transfusion in a fixed prede-
fined ratio carries the potential for wasting valuable
resources and the risk of complications (e.g. transfusion-
related acute lung injury, pathogen transmission).
AUVA TRAUMA HOSPITAL TREATMENT
ALGORITHM FOR TIC
EXTEM CA10 < 40 mm and FIBTEM CA10 > 12
mm and platelet count < 50,000/μL suggests suffi-
cient fibrin clot formation, but insufficient platelets
to produce adequate clot strength. Platelet concen-
trate transfusion is indicated.
Improving initiation of the coagulation process
Thrombin generation is not substantially affected in the
early stages of TIC [82]. Brohi et al. reported that gen-
eration of prothrombin fragment1-2 increased with
increasing ISS [83]. Thrombin generation in patients
with possible TIC (PT > 18 seconds or INR > 1.5) has
been reported as threefold higher than in controls (p =
0.01) [17]. The concept of of early, high-dose FFP trans-
fusion with the aim of increasing thrombin generation
must be debated in the light of adequate or even
increased thrombin generation in trauma patients upon
admission to the ER.
Coagulation time (CT) in ROTEM or reaction time (r-
time) in TEG serve as surrogate markers for the speed of
initiation of coagulation and can be considered as the
whole-blood PT or aPTT. Weiss et al. studied PTI, aPTT,
EXTEM CT and INTEM CT in a dilution model [84]. A
linear relationship was observed between either PTI or
aPTT and the concentration of coagulation factors. How-
ever, EXTEM CT remained < 80 seconds (normal range)
until coagulation factor activity fell below ~35% of normal.
Therefore, in the AUVA treatment algorithm, EXTEM
CT > 80 seconds and INTEM CT > 240 seconds indi-
cate a need for treatment to improve thrombin genera-
tion (Figure 2).
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Current options for increasing thrombin generation
during trauma-related bleeding include FFP, prothrom-
bin complex concentrate (PCC) and activated recombi-
nant factor VII (rFVIIa) [8,37,85-87]. rVIIa was studied
in two randomized controlled trials and failed to show a
survival benefit [85,88].
Limited data on the use of PCC in trauma are cur-
rently available. In one study, administration of fibrino-
gen concentrate (n = 128), along with PCC (n = 98), in
trauma patients (n = 131) produced more favourable
survival rates than those predicted by the trauma injury
severity score (TRISS) or revised injury severity classifi-
cation (RISC) score [8]. Schöchl et al. also reported sig-
nificantly higher transfusion rates for RBC and PC
among trauma patients receiving haemostatic therapy
with allogeneic blood products only, compared with
those receiving coagulation factor concentrates [86].
However, no randomized controlled trials have been
conducted to investigate this concept.
Robust safety data are lacking for the use of PCCs in
the treatment of TIC. PCC is a procoagulant drug, and a
possible risk of thromboembolic adverse events must be
considered alongside patients’ possible tendency towards
thrombosis following trauma [79,89-91]. The risk of hae-
mostatic imbalance relating to the prothrombotic nature
of PCC therapy may be offset by the use of viscoelastic
coagulation monitoring (EXTEM CT) to minimize the
risk of excessive dosing. Although some PCCs contain
the anticoagulant proteins C, S and Z, the main antago-
nist of factor II (antithrombin, ATIII) is either absent
from PCC or present in far smaller quantities than would
be needed to balance the procoagulant potential of factor
II [92]. In addition, the administered quantity of factor II
may be higher than that suggested by the labeled dose,
because PCCs are standardized according to factor IX (e.
g. in one product investigated by Kalina et al., the ratio of
FII:FIX was 1.6) [92]. Co-administration of ATIII with
PCC may be an option, particularly in patients with a
lack of coagulation inhibitors. When time is available (e.
g. oozing bleeding, in either the operating room or the
ICU), the plasma ATIII level should be measured before
PCC administration. However, clinical trial data are
needed to confirm best practice regarding potential
ATIII co-administration.
AUVA TRAUMA HOSPITAL TREATMENT
ALGORITHM FOR TIC
Prolongation of EXTEM CT > 80 seconds
1. Rule out the following reasons for CT
prolongation:
fibrinolysis (APTEM CT < EXTEM CT [not well
established for assessing fibrinolysis])
heparin effect (HEPTEM CT < INTEM CT [e.g.
following transfusion of cell- saver blood].
2. EXTEM CT > 80 seconds serves as a surrogate
parameter for insufficient thrombin generation. PCC
is a treatment option for improving thrombin
production.
Improvement of clot stability
Hyperfibrinolysis is associated with high mortality and
increased risk of MT [13-15]. Kashuk et al. reported
that even a small reduction (1 unit) in TEG clot
strength (G value) 1 hour post-injury increased mortality
by > 10%, and that primary fibrinolysis occurs in a
higher percentage of patients requiring MT than in the
overall group of trauma patients (34% vs. 18%) [13].
These observations are in line with data from the
CRASH-2 study which showed an improved survival rate
in patients receiving early antifibrinolytic therapy (tranexa-
mic acid [TXA] 1 g over 10 minutes followed by an infu-
sion of 1 g over 8 hours). Mortality in the placebo group
was 16%, whereas in the TXA group it was 14.5% [87].
Surprisingly, mortality was increased among patients
receiving TXA later than 3 hours post-trauma [93].
AUVA TRAUMA HOSPITAL TREATMENT
ALGORITHM FOR TIC
TXA (15-20 mg per kg bodyweight) should be admi-
nistered to all major trauma patients (ISS > 16), to
all trauma patients admitted in shock, and to all
trauma patients with hyperfibrinolysis confirmed by
ROTEM test results (any major improvement in
APTEM parameters compared to corresponding
EXTEM parameters).
Figure 2 depicts the “theragnostic” algorithm estab-
lished in the AUVA Trauma Hospital, Salzburg, and Fig-
ure 3 displays an example of a severe bleeding patient
treated according to this algorithm. The algorithm is
not currently supported by data from randomized con-
trolled trials, but clinical evidence has indicated its viabi-
lity in terms of safety and effectiveness [8,86]. Because
of the poor evidence base and international variations in
the approval status of coagulation factor concentrates, it
would be inappropriate to advocate widespread adoption
at this stage. However, the lack of well-designed rando-
mized controlled trials supporting the use of allogeneic
blood products must also be considered [94], together
with the empirical advantages of individualized, goal-
directed therapy.
Conclusion
The “theragnostic” concept is based on rapidly available
whole-blood viscoelastic test results. Haemostatic ther-
apy is individualized according to the patient’s actual
needs. Compared with predefined ratio-driven
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approaches to administering allogeneic blood products,
individualized coagulation management potentially
reduces the risks of both under-transfusion (increased
risk of bleeding) and over-transfusion (increased risk of
ARDS, acute lung injury, sepsis and MOF). Coagulation
factor concentrates offer possible advantages over FFP,
but the potential risks must be considered carefully. To
confirm the efficacy and safety of individualized haemo-
static management based on coagulation viscoelastic
tests, randomized controlled studies are mandatory.
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